Kacper Karaban, Dorota Słupik, Aleksandra Reda, Magdalena Gajewska, Bartosz Rolek, Josip A. Borovac, Panteleimon E. Papakonstantinou, Dario Bongiovanni, Hanne Ehrlinder, William A. E. Parker, Aleksander Siniarski, Aleksandra Gąsecka
- Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.
